Forkhead box O3 serves as a key downstream target of Mettl3, and downregulation of Mettl3 mediates the forkhead box O3 signaling pathway to enhance autophagy in HCC, thereby enhancing resistance to sorafenib.[67] Apatinib is a new VEGFR targeting agent, which is 10 times more potent than sorafenib. The gene discussed is METTL3; the disease is hepatocellular carcinoma.